What we do Nectar Lifescience Ltd is a global pharmaceutical company specializing in manufacturing and marketing of cephalosporin APIs, sterile injectables, and phytochemicals with certified plants. |
Founded in 1,995 |
Market share World's leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil, and Sterile APIs with a strong global presence. |
Problem solved Provides high-quality cephalosporin antibiotics and phytochemicals to address antimicrobial and therapeutic needs globally. |
Top clients or who we serve Supplies pharmaceutical companies globally; business-to-business focus with contract manufacturing for other pharma players. |
Key management Mr. Sanjiv Goyal, Chairman & Managing Director; Dr. Surulichamy Senthilkumar, Director (R&D). |
Our journey and innovations Incorporated in 1995; expanded capacity over years; introduced sterile injectable & phytochemical segments; launched innovative menthol capsule products recently. |
Where we operate Operations primarily in India; exports to international markets including US, Japan, UK, and Portugal via subsidiaries. |
Top products or what we offer Oral and sterile cephalosporin APIs, phytochemicals (menthol), empty hard gelatin capsules, contract manufacturing services. |
Top brands Leading cephalosporin APIs including Cefixime Trihydrate, Cefuroxime Axetil; Nexxicap MintyTM and PearlTM menthol capsules introduced in 2023. |
Raw materials needed Cephalosporin intermediates, menthol, raw chemicals for APIs and capsule manufacturing. |
Raw materials supplier Chempharma Pvt Ltd (wholly-owned subsidiary) for API intermediates; other chemical suppliers as per industry norms. |
Recurring vs cyclical contribution Revenue largely recurring from long-term manufacturing contracts; some cyclical impact from product demand fluctuations. |
Our industry position Top global position in select cephalosporin APIs; recognized for quality and multi-purpose manufacturing capabilities. |
Financial highlights FY 2024-25 revenue ₹1669.97 crore; net loss of ₹113.68 crore due to inventory markdown and sale transaction adjustments. |
Geographical revenue split India accounts for ₹1171.58 crore; Outside India revenue at ₹736.82 crore for FY 2024-25. |
Order book - |
Whats driving growth Innovation in sterile injectables, expansion in phytochemicals, and increasing global antibiotic demand drive growth. |
Our future plans Utilizing sale proceeds for debt repayment, new projects, dividends, or equity buyback; focusing on strategic core areas. |
Our green promise - |
Our people and values Committed to ethical business conduct with emphasis on governance and employee welfare; strong compliance culture. |
Key challenges ahead Managing debt, adapting to market competition, inventory management, and post-sale business restructuring. |
Interesting facts World's leading producer of key cephalosporin APIs; pioneered menthol capsule innovation in India in 2023. |
Risks and strategy Mitigate financial stress through asset sales; maintain manufacturing excellence; diversify product portfolio and markets. |
